Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Chem Res Toxicol ; 18(3): 415-9, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15777081

RESUMO

We report a new and specific mechanism for iron-mediated neurotoxicity using RCHT cells, which were derived from rat hypothalamus. RCHT cells exhibit immunofluorescent-positive markers for dopamine beta-hydroxylase and the norepinephrine transporter, NET. In the present study, we observed that iron-induced neurotoxicity in RCHT cells was dependent on (i) formation of an Fe-dopamine complex (100 microM FeCl3:100 microM dopamine); (ii) specific uptake of the Fe-dopamine complex into RCHT cells via NET (79+/-2 pmol 59Fe/mg/min; P<0.05), since the uptake of the 59Fe-dopamine complex by the cells was inhibited by 30 microM reboxetine, a specific NET inhibitor (78% inhibition, P<0.001); and (iii) intracellular oxidation of dopamine present in the Fe-dopamine complex to aminochrome; (iv) inhibition of DT-diaphorase, since incubation of RCHT cells with 100 microM Fe-dopamine complex in the presence of 100 microM dicoumarol, an inhibitor of DT-diaphorase, induced significant cell death (51+/-5%; P<0.001). However, this cell death was reduced by 75% when the cells were incubated in the presence of 30 microM reboxetine (P<0.01). No significant cell death was observed when the cells were incubated with 100 microM dopamine, 100 microM Fe-Dopamine complex, 100 microM dicoumarol, or 100 microM FeCl3 (8.3+/-2, 9+/-4, 8.5+/-3, or 9.7+/-2% of control, respectively). ESR studies using the spin trapping agent DMPO showed no formation of hydroxyl radicals when the cells were incubated with 100 microM FeCl3 alone. However, using the same ESR technique, the formation of hydroxyl radicals and a carbon-centered radical was detected when the cells were incubated with 100 microM Fe-dopamine complex in the presence of 100 microM dicoumarol. These studies suggest that iron can induce cell toxicity by a mechanism that requires the formation and NET-mediated uptake of an Fe-dopamine complex, ultimately resulting in the intracellular formation of reactive species.


Assuntos
Dopamina/metabolismo , Compostos Férricos/metabolismo , Hipotálamo/efeitos dos fármacos , Ferro/toxicidade , Inibidores da Captação Adrenérgica/farmacologia , Animais , Morte Celular/efeitos dos fármacos , Linhagem Celular , Cloretos , Dicumarol/farmacologia , Dopamina/farmacologia , Dopamina beta-Hidroxilase/metabolismo , Imunofluorescência , Hipotálamo/enzimologia , Hipotálamo/patologia , Indolquinonas/metabolismo , Ferro/metabolismo , Microscopia Confocal , Morfolinas/farmacologia , NAD(P)H Desidrogenase (Quinona)/antagonistas & inibidores , Proteínas da Membrana Plasmática de Transporte de Norepinefrina , Ratos , Ratos Endogâmicos F344 , Reboxetina , Simportadores/metabolismo
2.
J Neurochem ; 92(5): 1021-32, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15715653

RESUMO

The role of dopamine in iron uptake into catecholaminergic neurons, and dopamine oxidation to aminochrome and its one-electron reduction in iron-mediated neurotoxicity, was studied in RCSN-3 cells, which express both tyrosine hydroxylase and monoamine transporters. The mean +/- SD uptake of 100 microm 59FeCl3 in RCSN-3 cells was 25 +/- 4 pmol per min per mg, which increased to 28 +/- 8 pmol per min per mg when complexed with dopamine (Fe(III)-dopamine). This uptake was inhibited by 2 microm nomifensine (43%p < 0.05), 100 microm imipramine (62%p < 0.01), 30 microm reboxetine (71%p < 0.01) and 2 mm dopamine (84%p < 0.01). The uptake of 59Fe-dopamine complex was Na+, Cl- and temperature dependent. No toxic effects in RCSN-3 cells were observed when the cells were incubated with 100 microm FeCl3 alone or complexed with dopamine. However, 100 microm Fe(III)-dopamine in the presence of 100 microm dicoumarol, an inhibitor of DT-diaphorase, induced toxicity (44% cell death; p < 0.001), which was inhibited by 2 microm nomifensine, 30 microm reboxetine and 2 mm norepinephrine. The neuroprotective action of norepinephrine can be explained by (1) its ability to form complexes with Fe3+, (2) the uptake of Fe-norepinephrine complex via the norepinephrine transporter and (3) lack of toxicity of the Fe-norepinephrine complex even when DT-diaphorase is inhibited. These results support the proposed neuroprotective role of DT-diaphorase and norepinephrine.


Assuntos
Dopamina/metabolismo , Ferro/toxicidade , Moduladores de Transporte de Membrana , Proteínas de Membrana Transportadoras/antagonistas & inibidores , Neurônios/efeitos dos fármacos , Norepinefrina/farmacologia , Substância Negra/citologia , Inibidores da Captação Adrenérgica/farmacologia , Análise de Variância , Animais , Proteínas da Membrana Plasmática de Transporte de Catecolaminas , Morte Celular/efeitos dos fármacos , Células Cultivadas , Cloretos/metabolismo , Dicumarol/farmacologia , Proteínas da Membrana Plasmática de Transporte de Dopamina , Inibidores da Captação de Dopamina , Relação Dose-Resposta a Droga , Espectroscopia de Ressonância de Spin Eletrônica/métodos , Embrião de Mamíferos , Inibidores Enzimáticos/farmacologia , Compostos Férricos/metabolismo , Compostos Férricos/farmacologia , Imunofluorescência/métodos , Imipramina/farmacologia , Indolquinonas/farmacologia , Isótopos de Ferro/farmacologia , Glicoproteínas de Membrana/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Microscopia Confocal/métodos , Modelos Biológicos , Morfolinas/farmacologia , Proteínas do Tecido Nervoso/metabolismo , Neurônios/metabolismo , Nomifensina/farmacologia , Proteínas da Membrana Plasmática de Transporte de Norepinefrina , Ratos , Ratos Endogâmicos F344 , Ratos Wistar , Reboxetina , Proteínas da Membrana Plasmática de Transporte de Serotonina , Sódio/metabolismo , Simportadores/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Tirosina 3-Mono-Oxigenase/metabolismo
3.
Neurobiol Dis ; 16(2): 468-77, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15193303

RESUMO

Leukoaminochrome o-semiquinone radical is generated during one-electron reduction of dopamine oxidation product aminochrome when DT-diaphorase is inhibited. Incubation of 100 microM aminochrome with 100 microM dicoumarol, an inhibitor of DT-diaphorase during 2 h, induces 56% cell death (P < 0.001) with concomitant formation of (i) intracellular hydroperoxides (4.2-fold increase compared to control; P < 0.001); (ii) hydroxyl radicals, detected with ESR and spin trapping agents (2.4-fold increase when cells were incubated with aminochrome in the presence of dicoumarol compared to aminochrome alone); (iii) intracellular edema, and cell membrane deterioration determined by transmission electron microscopy; (iv) absence of apoptosis, supported by using anexin-V with flow cytometry; (v) a strong decrease of mitochondrial membrane potential determined by the fluorescent dye 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanineiodide (P < 0.01); (vi) swelling and disruption of outer and inner mitochondrial membranes determined by transmission electron microscopy. These results support the proposed role of leukoaminochrome o-semiquinone radical as neurotoxin in Parkinson's disease neurodegeneration and DT-diaphorase as neuroprotective enzyme.


Assuntos
Benzoquinonas/metabolismo , Dopamina/metabolismo , Mitocôndrias/metabolismo , Degeneração Neural/metabolismo , Neurônios/metabolismo , Neurotoxinas/metabolismo , Animais , Linhagem Celular , Radical Hidroxila/metabolismo , Potenciais da Membrana/fisiologia , Necrose , Neurônios/patologia , Neurônios/fisiologia , Oxirredução , Ratos , Ratos Endogâmicos F344 , Substância Negra/citologia , Superóxido Dismutase/metabolismo
4.
Pol J Pharmacol ; 54(6): 573-9, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12866711

RESUMO

Although it is generally accepted that free radicals are involved in the neurodegenerative process occurring in the dopaminergic neurons of the nigro-striatal system in Parkinson's disease, the exact mechanism of neurodegeneration in vivo is still unknown. We propose that the degeneration of dopaminergic nigrostriatal system in this condition may depend on: (a) existence of free dopamine which oxidizes to aminochrome as a consequence of: (i) overproduction of dopamine; (ii) inhibition and/or low expression of synaptic vesicle catecholamine transporter; (iii) inhibition or low expression of monoamine oxidases; (b) one-electron reduction of aminochrome to leukoaminochrome o-semiquinone radical, which induces neurotoxicity, due to inhibition of DT-diaphorase or the existence of a polymorphism with a point mutation (C --> T) in the cDNA 609 expressing an inactive DT-diaphorase. We suggest that DT-diaphorase plays a neuroprotective role in dopaminergic neurons, which is supported by the following observations: (i) Cu-toxicity is dependent on DT-diaphorase inhibition with dicoumarol in RCSN-3 cells derived from the rat substantia nigra; (ii) the cytotoxic effect of monoamine oxidase-A inhibitor amiflamine in RCSN-3 cells is increased by 2.4-fold (p < 0.001) in the presence of the inhibitor of DT-diaphorase, dicoumarol; (iii) concomitant intracerebral administration of manganese (Mn3+) together with the DT-diaphorase inhibitor dicoumarol into the left medial forebrain bundle produced a behavioral pattern characterized by contralateral rotational behavior when the rats were stimulated with apomorphine, in a manner similar to that observed in animals injected unilaterally with 6-hydroxydopamine; (iv) incubation of RCSN-3 cells with salsolinol in the presence of DT-diaphorase inhibitor significantly decreased cell survival by 2.5-fold (p < 0.001).


Assuntos
Dopamina/metabolismo , Indolquinonas , Indóis/metabolismo , NAD(P)H Desidrogenase (Quinona)/fisiologia , Fármacos Neuroprotetores/farmacologia , Doença de Parkinson/metabolismo , Animais , Dopamina/fisiologia , Humanos , Indóis/farmacologia , NAD(P)H Desidrogenase (Quinona)/metabolismo , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/metabolismo , Fármacos Neuroprotetores/uso terapêutico , Oxirredução/efeitos dos fármacos , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...